Sign in

CIK 0001818844

  • Non-accelerated filer
  • Smaller reporting company

Dogwood Therapeutics, Inc.

Sign in to watch
Ticker
DWTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
854314201
Phone
+1 866-620-8655
Business address
44 MILTON AVENUE, ALPHARETTA, GA, 30009
Former names
Virios Therapeutics, Inc., Virios Therapeutics, LLC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-10-26 Sealbond Ltd Director Grant or award +4,098,360 $1.22 $5.0M 25,920,693
2026-06-16 Keefer David R Director Grant or award · Stock Option (right to buy) +16,800 16,800
2026-06-16 De La Rosa Abel Director Grant or award · Stock Option (right to buy) +16,800 16,800
2026-06-16 Whitley Richard James Director Grant or award · Stock Option (right to buy) +16,800 16,800
2026-06-16 Thomas John C Director Grant or award · Stock Option (right to buy) +16,800 16,800
2026-03-05 Duncan Gregory Scott CHIEF EXECUTIVE OFFICER Grant or award · Stock Option (right to buy) +330,000 330,000
2026-03-05 Gendreau Roger Michael CHIEF MEDICAL OFFICER Grant or award · Stock Option (right to buy) +82,500 82,500
2026-03-05 Grosswald Ralph SVP OF OPERATIONS Grant or award · Stock Option (right to buy) +82,500 82,500
2026-03-05 Walsh Angela Chief Financial Officer Grant or award · Stock Option (right to buy) +82,500 82,500
2025-12-04 Duncan Gregory Scott CHIEF EXECUTIVE OFFICER Grant or award · Stock Option (right to buy) +460,000 460,000
2025-12-04 Gendreau Roger Michael CHIEF MEDICAL OFFICER Grant or award · Stock Option (right to buy) +150,000 150,000
2025-12-04 Grosswald Ralph SVP OF OPERATIONS Grant or award · Stock Option (right to buy) +150,000 150,000
2025-12-04 Walsh Angela Chief Financial Officer Grant or award · Stock Option (right to buy) +150,000 150,000
2025-11-21 Sealbond Ltd Director Conversion +21,610,950 21,822,333
2025-11-21 Sealbond Ltd Director Conversion +2,842,638 2,842,638
2025-11-21 Sealbond Ltd Director Conversion · Series A Preferred Stock −2,161.1 0
2025-11-21 Sealbond Ltd Director Conversion · Series A-1 Preferred Stock −284.26 0
2025-06-27 Gendreau Roger Michael CHIEF MEDICAL OFFICER Grant or award · Stock Option (right to buy) +12,075 12,075
2025-06-27 Whitley Richard James Director Grant or award · Stock Option (right to buy) +2,362 2,362
2025-06-27 Grosswald Ralph SVP OF OPERATIONS Grant or award · Stock Option (right to buy) +12,075 12,075

Page 1 of 6 · 113 trades